Expression and Prognosis Analyses of Runt-Related Transcription Factor Family in Human Leukemia.


:Despite advances in early diagnosis and treatment, cancer remains the major reason for mortality worldwide. The Runt-related transcription factor (RUNX) family has been reported to participate in diverse human diseases. However, little is known about their expression and prognostic values in human leukemia. Herein, we conducted a detailed cancer versus normal analysis. The mRNA expression levels of the RUNX family in various kinds of cancers, including leukemia, were analyzed via the ONCOMINE and GEPIA (Gene Expression Profiling Interactive Analysis) databases. We observed that the mRNA expression levels of RUNX1, RUNX2, and RUNX3 were all increased in most cancers compared with normal tissues, especially in leukemia. Moreover, the expression levels of RUNX1, RUNX2, and RUNX3 are also highly expressed in almost all cancer cell lines, particularly in acute myeloid leukemia (AML) cell lines, analyzed by Cancer Cell Line Encyclopedia (CCLE) and European Bioinformatics Institute (EMBL-EBI) databases. Further, the LinkedOmics and GEPIA databases were used to evaluate the prognostic values. In survival analyses based on LinkedOmics, higher expression of RUNX1 and RUNX2 indicated a better overall survival (OS), but with no significance, whereas increased RUNX3 revealed a poor OS in leukemia. In addition, the GEPIA dataset was also used to perform survival analyses, and results manifested that the expression of RUNX1 and RUNX2 had no remarkable correction with OS in leukemia, but it showed highly expressed RUNX3 was significantly related with poor OS in leukemia. In conclusion, the RUNX family showed significant expression differences between cancer and normal tissues, especially leukemia, and RUNX3 could be a promising prognostic biomarker for leukemia.


Mol Ther Oncolytics


Sun CC,Li SJ,Chen ZL,Li G,Zhang Q,Li DJ




Has Abstract


2018-12-18 00:00:00










  • Chemovirotherapy of Pancreatic Adenocarcinoma by Combining Oncolytic Vaccinia Virus GLV-1h68 with nab-Paclitaxel Plus Gemcitabine.

    abstract::Oncolytic viruses have proven their therapeutic potential against a variety of different tumor entities both in vitro and in vivo. Their ability to selectively infect and lyse tumor cells, while sparing healthy tissues, makes them favorable agents for tumor-specific treatment approaches. Particularly, the addition of ...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章


    authors: Binz E,Berchtold S,Beil J,Schell M,Geisler C,Smirnow I,Lauer UM

    更新日期:2017-04-19 00:00:00

  • Hypomethylation Causes MIR21 Overexpression in Tumors.

    abstract::miR-21 is an oncogenic microRNA (miRNA) that is upregulated in many solid tumors. However, the effect of MIR21 hypomethylation on miR-21 expression in tumors and the mechanism of miR-21 DNA demethylation remain unclear. In this study, we confirmed that the expression of miR-21 was significantly increased in multiple t...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章


    authors: Lu J,Tan T,Zhu L,Dong H,Xian R

    更新日期:2020-05-26 00:00:00

  • RBFOX1 Regulates the Permeability of the Blood-Tumor Barrier via the LINC00673/MAFF Pathway.

    abstract::The blood-tumor barrier limits the delivery of therapeutic drugs to brain tumor tissues. Selectively opening the blood-tumor barrier is considered crucial for effective chemotherapy of glioma. RNA-binding proteins have emerged as crucial regulators in various biologic processes. This study found that RNA-binding Fox-1...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章


    authors: Shen S,Yang C,Liu X,Zheng J,Liu Y,Liu L,Ma J,Ma T,An P,Lin Y,Cai H,Wang D,Li Z,Zhao L,Xue Y

    更新日期:2020-03-30 00:00:00

  • A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer.

    abstract::Therapeutic targeting of advanced or metastatic non-small-cell lung cancer (NSCLC) represents a major goal of clinical treatment. Polo-like kinase 1 (PLK1) is an essential mitotic kinase in cell cycle progression and is associated with oncogenesis in a large spectrum of cancer types, including NSCLC. Volasertib (BI 67...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章


    authors: Li L,Xue W,Shen Z,Liu J,Hu M,Cheng Z,Wang Y,Chen Y,Chang H,Liu Y,Liu B,Zhao J

    更新日期:2020-06-23 00:00:00

  • Oncolytic Herpes Simplex Virus Prevents Premalignant Lesions from Progressing to Cancer.

    abstract::Early detection and timely treatment of precancerous lesions are hallmarks of successful strategies to prevent deaths due to cancer. Oncolytic viruses are a group of promising anti-cancer agents with wide-ranging experimental and clinical efficacy against solid tumors. Previously, we have shown that NV1066, an oncolyt...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章


    authors: Woo Y,Reid V,Kelly KJ,Carlson D,Yu Z,Fong Y

    更新日期:2019-12-06 00:00:00

  • Glioblastoma Bystander Cell Therapy: Improvements in Treatment and Insights into the Therapy Mechanisms.

    abstract::A preclinical model of glioblastoma (GB) bystander cell therapy using human adipose mesenchymal stromal cells (hAMSCs) is used to address the issues of cell availability, quality, and feasibility of tumor cure. We show that a fast proliferating variety of hAMSCs expressing thymidine kinase (TK) has therapeutic capacit...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章


    authors: Guerra-Rebollo M,Nogueira de Moraes C,Alcoholado C,Soler-Botija C,Sanchez-Cid L,Vila OF,Meca-Cortés O,Ramos-Romero S,Rubio N,Becerra J,Blanco J,Garrido C

    更新日期:2018-09-15 00:00:00

  • Irisin Is a Positive Regulator for Ferroptosis in Pancreatic Cancer.

    abstract::Regulated cell death by way of ferroptosis involves iron-dependent accumulation of cellular reactive oxygen species (ROS). Ferroptosis is attracting attention as a potential therapeutic target for cancer treatments without drug resistance. The relationship between irisin, a myokine involved in autophagy and ROS metabo...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章


    authors: Yang BC,Leung PS

    更新日期:2020-08-05 00:00:00

  • Oncolytic Herpes Virus rRp450 Shows Efficacy in Orthotopic Xenograft Group 3/4 Medulloblastomas and Atypical Teratoid/Rhabdoid Tumors.

    abstract::Pediatric brain tumors including medulloblastoma and atypical teratoid/rhabdoid tumor are associated with significant mortality and treatment-associated morbidity. While medulloblastoma tumors within molecular subgroups 3 and 4 have a propensity to metastasize, atypical teratoid/rhabdoid tumors frequently afflict a ve...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章


    authors: Studebaker AW,Hutzen BJ,Pierson CR,Haworth KB,Cripe TP,Jackson EM,Leonard JR

    更新日期:2017-05-25 00:00:00

  • Chimeric Antigen Receptor T Cell Bearing Herpes Virus Entry Mediator Co-stimulatory Signal Domain Exhibits High Functional Potency.

    abstract::Chimeric antigen receptor (CAR) is a hybrid molecule consisting of an antigen-binding domain and a signal transduction domain. The artificial T cells expressing CAR (CAR-T cells) are expected to be a useful tool for treatment of various diseases, such as cancer. The addition of a co-stimulatory signal domain (CSSD) to...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章


    authors: Nunoya JI,Masuda M,Ye C,Su L

    更新日期:2019-03-23 00:00:00

  • Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPVPOS Cancers.

    abstract::Immunotherapy for HPVPOS malignancies is attractive because well-defined, viral, non-self tumor antigens exist as targets. Several approaches to vaccinate therapeutically against HPV E6 and E7 antigens have been adopted, including viral platforms such as VSV. A major advantage of VSV expressing these antigens is that ...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章


    authors: Suksanpaisan L,Xu R,Tesfay MZ,Bomidi C,Hamm S,Vandergaast R,Jenks N,Steele MB,Ota-Setlik A,Akhtar H,Luckay A,Nowak R,Peng KW,Eldridge JH,Clarke DK,Russell SJ,Diaz RM

    更新日期:2018-07-05 00:00:00

  • The m6A-Related mRNA Signature Predicts the Prognosis of Pancreatic Cancer Patients.

    abstract::N6-methyladenosine (m6A) has an important epitranscriptomic modification that controls cancer self-renewal and cell fate. The addition of m6A to mRNA is a reversible modification. The deposition of m6A is encoded by a methyltransferase complex involving three homologous factors, jargonized as "writers," "erasers," and...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章


    authors: Meng Z,Yuan Q,Zhao J,Wang B,Li S,Offringa R,Jin X,Wu H

    更新日期:2020-04-29 00:00:00

  • miR-16-5p/PDK4-Mediated Metabolic Reprogramming Is Involved in Chemoresistance of Cervical Cancer.

    abstract::Cervical cancer is one of the most prevalent malignancies in women worldwide. Therefore, investigation about molecular pathogenesis and related therapy targets of cervical cancer is an emergency. The molecular mechanisms responsible for the chemoresistance of cervical cancer were investigated by the use of doxorubicin...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章


    authors: Zhao Z,Ji M,Wang Q,He N,Li Y

    更新日期:2020-05-23 00:00:00

  • B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma.

    abstract::Glioblastoma (GBM) remains one of the most malignant primary tumors in adults, with a 5-year survival rate less than 10% because of lacking effective treatment. Here, we aimed to explore whether B7-H3 could serve as a novel therapeutic target for GBM in chimeric antigen receptor (CAR) T cell therapy. In this study, a ...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章


    authors: Tang X,Zhao S,Zhang Y,Wang Y,Zhang Z,Yang M,Zhu Y,Zhang G,Guo G,Tong A,Zhou L

    更新日期:2019-07-23 00:00:00

  • Assessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly"?

    abstract::Over the past two decades, a considerable amount of oncolytic vector families has entered numerous clinical trials. However, to this date, the field has not yet been able to come to a common understanding regarding the best possible ways to administer oncolytic viruses to cancer patients. This is mainly due to the fac...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章,评审


    authors: Ruf B,Lauer UM

    更新日期:2015-11-04 00:00:00

  • Doxorubicin Conjugation to Reovirus Improves Oncolytic Efficacy in Triple-Negative Breast Cancer.

    abstract::Breast cancer is the second leading cause of cancer-related deaths in women in the United States. The triple-negative breast cancer (TNBC) subtype associates with higher rates of relapse, shorter overall survival, and aggressive metastatic disease. Hormone therapy is ineffective against TNBC, leaving patients with lim...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章


    authors: Berry JTL,Muñoz LE,Rodríguez Stewart RM,Selvaraj P,Mainou BA

    更新日期:2020-08-21 00:00:00

  • The Role of Adaptor Protein CARD9 in Colitis-Associated Cancer.

    abstract::The adaptor protein CARD9 plays an important role in anti-fungal immunity responses, linking detection of fungi by surface receptors to activation of the transcription factor nuclear factor κB (NF-κB). Recent studies indicate that CARD9 also plays different but vital roles during the development of colitis-associated ...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章,评审


    authors: Zhong X,Chen B,Liu M,Yang Z

    更新日期:2019-08-30 00:00:00

  • Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity.

    abstract::Multiple studies have indicated that in addition to direct oncolysis, virotherapy promotes an antitumor cytotoxic T cell response important for efficacy. To study this phenomenon further, we tested three syngeneic murine sarcoma models that displayed varied degrees of permissiveness to oncolytic herpes simplex virus r...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章


    authors: Leddon JL,Chen CY,Currier MA,Wang PY,Jung FA,Denton NL,Cripe KM,Haworth KB,Arnold MA,Gross AC,Eubank TD,Goins WF,Glorioso JC,Cohen JB,Grandi P,Hildeman DA,Cripe TP

    更新日期:2015-01-21 00:00:00

  • Bacterial Carriers for Glioblastoma Therapy.

    abstract::Treatment of aggressive glioblastoma brain tumors is challenging, largely due to diffusion barriers preventing efficient drug dosing to tumors. To overcome these barriers, bacterial carriers that are actively motile and programmed to migrate and localize to tumor zones were designed. These carriers can induce apoptosi...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章


    authors: Mehta N,Lyon JG,Patil K,Mokarram N,Kim C,Bellamkonda RV

    更新日期:2016-12-14 00:00:00

  • Analysis and Augmentation of the Immunologic Bystander Effects of CAR T Cell Therapy in a Syngeneic Mouse Cancer Model.

    abstract::The therapeutic efficacy of adoptive transfer of T cells transduced with chimeric antigen receptors (CARs) has been limited in the treatment of solid cancers, partly due to tumor antigen heterogeneity. Overcoming lack of universal tumor antigen expression would be achieved if CAR T cells could induce bystander effects...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章


    authors: Klampatsa A,Leibowitz MS,Sun J,Liousia M,Arguiri E,Albelda SM

    更新日期:2020-07-15 00:00:00

  • Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment.

    abstract::Oncolytic viruses (OVs) are novel anti-tumor agents with the ability to selectively infect and kill tumor cells while sparing normal tissue. Beyond tumor cytolysis, OVs are capable of priming an anti-tumor immune response via lysis and cross-presentation of locally expressed endogenous tumor antigens, acting as an "en...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章


    authors: De Lucia M,Cotugno G,Bignone V,Garzia I,Nocchi L,Langone F,Petrovic B,Sasso E,Pepe S,Froechlich G,Gentile C,Zambrano N,Campadelli-Fiume G,Nicosia A,Scarselli E,D'Alise AM

    更新日期:2020-10-14 00:00:00

  • High-content molecular profiling of T-cell therapy in oncology.

    abstract::Recent clinical data have revealed the remarkable potential for T-cell-modulating agents to induce potent and durable responses in a subset of cancer patients. In this review, we discuss molecular approaches, platforms, and strategies that enable a broader interrogation of the activity of agents that modulate the acti...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章,评审


    authors: Novosiadly R,Kalos M

    更新日期:2016-03-30 00:00:00

  • Insertion of the Type-I IFN Decoy Receptor B18R in a miRNA-Tagged Semliki Forest Virus Improves Oncolytic Capacity but Results in Neurotoxicity.

    abstract::Oncolytic Semliki Forest virus (SFV) has been suggested as a potential candidate for the treatment of glioblastoma and neuroblastoma. However, the oncolytic capacity of SFV is restricted by the anti-viral type-I interferon (IFN) response. The aim of this study was to increase the oncolytic capacity of a microRNA targe...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章


    authors: Sarén T,Ramachandran M,Martikainen M,Yu D

    更新日期:2017-10-05 00:00:00

  • Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma.

    abstract::Oncolytic viruses (OVs) are emerging as powerful anti-cancer agents and are currently being tested for their safety and efficacy in patients. Reovirus (Reolysin), a naturally occurring non-pathogenic, double-stranded RNA virus, has natural oncolytic activity and is being tested in phase I-III clinical trials in a vari...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章


    authors: Jaime-Ramirez AC,Yu JG,Caserta E,Yoo JY,Zhang J,Lee TJ,Hofmeister C,Lee JH,Kumar B,Pan Q,Kumar P,Baiocchi R,Teknos T,Pichiorri F,Kaur B,Old M

    更新日期:2017-05-10 00:00:00

  • Non-signaling Chimeric Antigen Receptors Enhance Antigen-Directed Killing by γδ T Cells in Contrast to αβ T Cells.

    abstract::Chimeric antigen receptor (CAR)-modified T cells have demonstrated efficacy against B cell leukemias/lymphomas. However, redirecting CAR T cells to malignant T cells is more challenging due to product-specific cis- and trans-activation causing fratricide. Other challenges include the potential for product contaminatio...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章


    authors: Fleischer LC,Becker SA,Ryan RE,Fedanov A,Doering CB,Spencer HT

    更新日期:2020-06-04 00:00:00

  • Molecular network, pathway, and functional analysis of time-dependent gene changes associated with pancreatic cancer susceptibility to oncolytic vaccinia virotherapy.

    abstract:BACKGROUND:Pancreatic cancer is a fatal disease associated with resistance to conventional therapies. This study aimed to determine changes in gene expression patterns associated with infection and susceptibility of pancreatic cancer cells to an oncolyticvaccinia virus, GLV-1h153, carrying the human sodium iodide sympo...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章


    authors: Haddad D,Socci N,Chen CH,Chen NG,Zhang Q,Carpenter SG,Mittra A,Szalay AA,Fong Y

    更新日期:2016-03-16 00:00:00

  • Overexpression of YBX1 Promotes Pancreatic Ductal Adenocarcinoma Growth via the GSK3B/Cyclin D1/Cyclin E1 Pathway.

    abstract::Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers due to frequently late diagnosis and futile treatment. It is a crucial necessity to determine the mechanisms of PDAC. Y-box Binding Protein 1 (YBX1), a highly conserved transcription factor, has been previously reported to play a role in various ...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章


    authors: Liu Z,Li Y,Li X,Zhao J,Wu S,Wu H,Gou S

    更新日期:2020-03-29 00:00:00

  • Efficacy of a Third-Generation Oncolytic Herpes Virus G47Δ in Advanced Stage Models of Human Gastric Cancer.

    abstract::Advanced gastric cancer, especially scirrhous gastric cancer with peritoneal dissemination, remains refractory to conventional therapies. G47Δ, a third-generation oncolytic herpes simplex virus type 1, is an attractive novel therapeutic agent for solid cancer. In this study, we investigated the therapeutic potential o...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章


    authors: Sugawara K,Iwai M,Yajima S,Tanaka M,Yanagihara K,Seto Y,Todo T

    更新日期:2020-04-08 00:00:00

  • Targeting Poxvirus Decapping Enzymes and mRNA Decay to Generate an Effective Oncolytic Virus.

    abstract::Through the action of two virus-encoded decapping enzymes (D9 and D10) that remove protective caps from mRNA 5'-termini, Vaccinia virus (VACV) accelerates mRNA decay and limits activation of host defenses. D9- or D10-deficient VACV are markedly attenuated in mice and fail to counter cellular double-stranded RNA-respon...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章


    authors: Burgess HM,Pourchet A,Hajdu CH,Chiriboga L,Frey AB,Mohr I

    更新日期:2018-01-31 00:00:00

  • Partial Deletion of Glycoprotein B5R Enhances Vaccinia Virus Neutralization Escape while Preserving Oncolytic Function.

    abstract::Vaccinia virus (VV) has been utilized in oncolytic virotherapy, but it risks a host antiviral immune response. VV has an extracellular enveloped virus (EEV) form consisting of a normal virion covered with a host-derived outer membrane that enables its spread via circulation while evading host immune mechanisms. Howeve...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章


    authors: Nakatake M,Kurosaki H,Kuwano N,Horita K,Ito M,Kono H,Okamura T,Hasegawa K,Yasutomi Y,Nakamura T

    更新日期:2019-05-21 00:00:00

  • CXCR4 Antagonist AMD3100 Reverses the Resistance to Tamoxifen in Breast Cancer via Inhibiting AKT Phosphorylation.

    abstract::Endocrine therapy is a systemic therapy and has become the main treatment strategy for patients with estrogen receptor (ER)-positive breast cancer. However, tamoxifen resistance has become an insurmountable clinical challenge, and the underlying mechanisms are still poorly understood. In this study, we explored the ro...

    journal_title:Molecular therapy oncolytics

    pub_type: 杂志文章


    authors: Zhou J,Le K,Xu M,Ming J,Yang W,Zhang Q,Lu L,Xi Z,Ruan S,Huang T

    更新日期:2020-06-24 00:00:00